Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90

Heat shock protein 90 (Hsp90) is an emerging therapeutic target of interest for the treatment of cancer. Its role in protein homeostasis and the selective chaperoning of key signaling proteins in cancer survival and proliferation pathways has made it an attractive target of small molecule therapeutic intervention. 17-Allylamino-17-demethoxygeldanamycin (17-AAG), the most studied agent directed against Hsp90, suffers from poor physical-chemical properties that limit its clinical potential. Therefore, there exists a need for novel, patient-friendly Hsp90-directed agents for clinical investigation. IPI-504, the highly soluble hydroquinone hydrochloride derivative of 17-AAG, was synthesized as an Hsp90 inhibitor with favorable pharmaceutical properties. Its biochemical and biological activity was profiled in an Hsp90-binding assay, as well as in cancer-cell assays. Furthermore, the metabolic profile of IPI-504 was compared with that of 17-AAG, a geldanamycin analog currently in clinical trials. The anti-tumor activity of IPI-504 was tested as both a single agent as well as in combination with bortezomib in myeloma cell lines and in vivo xenograft models, and the retention of IPI-504 in tumor tissue was determined. In conclusion, IPI-504, a potent inhibitor of Hsp90, is efficacious in cellular and animal models of myeloma. It is synergistically efficacious with the proteasome inhibitor bortezomib and is preferentially retained in tumor tissues relative to plasma. Importantly, it was observed that IPI-504 interconverts with the known agent 17-AAG in vitro and in vivo via an oxidation-reduction equilibrium, and we demonstrate that IPI-504 is the slightly more potent inhibitor of Hsp90.

[1]  A. King,et al.  A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Poggi,et al.  Clinical toxicity of cryopreserved circulating progenitor cells infusion. , 1998, Anticancer research.

[3]  S. Alkan,et al.  Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma , 2006, Leukemia & lymphoma.

[4]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[5]  J. Dice,et al.  Roles of molecular chaperones in protein degradation , 1996, The Journal of cell biology.

[6]  Srinivas Annavarapu,et al.  Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. , 2005, Blood.

[7]  J. Bladé,et al.  Moving forward in myeloma research. , 2004, Haematologica.

[8]  D. Ross.  Quinone Reductases Multitasking in the Metabolic World , 2004, Drug metabolism reviews.

[9]  James Bradner,et al.  Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.

[10]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Orrenius,et al.  The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells. , 1982, The Journal of biological chemistry.

[12]  A. Sartorelli.  Therapeutic attack of hypoxic cells of solid tumors: presidential address. , 1988, Cancer research.

[13]  S. Piantadosi,et al.  Clinical toxicity of cryopreserved bone marrow graft infusion. , 1990, Blood.

[14]  T G Myers,et al.  DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. , 1999, Journal of the National Cancer Institute.

[15]  F. Ritossa.  A new puffing pattern induced by temperature shock and DNP in drosophila , 1962, Experientia.

[16]  David Siegel,et al.  Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. , 2005, Cancer research.

[17]  James R. Porter,et al.  Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. , 2006, Journal of medicinal chemistry.

[18]  T. Libermann,et al.  Antimyeloma activity of heat shock protein-90 inhibition. , 2005, Blood.

[19]  Paul Workman,et al.  Overview: translating Hsp90 biology into Hsp90 drugs. , 2003, Current cancer drug targets.

[20]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[21]  M. Goetz,et al.  The Hsp90 chaperone complex as a novel target for cancer therapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[23]  L. Neckers,et al.  Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Diorio,et al.  Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. , 1995, Journal of medicinal chemistry.

[25]  A. Jaiswal,et al.  NAD(P)H:Quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues , 1993, Cancer and Metastasis Reviews.

[26]  M. Egorin,et al.  Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. , 1998, Cancer research.

[27]  C. Scheidereit,et al.  Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation , 2004, Oncogene.

[28]  P. Miller,et al.  erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. , 1995, Journal of medicinal chemistry.

[29]  Giulio Rastelli,et al.  Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. , 2003, Chemistry & biology.

[30]  D. Ross,et al.  NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. , 2004, Methods in enzymology.

[31]  B. Ames,et al.  Mutagenicity of quinones: pathways of metabolic activation and detoxification. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. L. Bergsagel,et al.  Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.

[33]  R. Bataille,et al.  Therapeutic implications of myeloma staging * , 1989, European journal of haematology. Supplementum.

[34]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[35]  V. Levin,et al.  Possible role of DT-diaphorase in the bioactivation of antitumor quinones. , 1983, Biochemical and biophysical research communications.

[36]  L. Neckers,et al.  Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. , 2004, Molecular cancer therapeutics.

[37]  E. Sausville,et al.  Clinical development of 17-allylamino, 17-demethoxygeldanamycin. , 2003, Current cancer drug targets.

[38]  F. Hartl.  Molecular chaperones in cellular protein folding , 1996, Nature.